Caxton Associates (New York)’s PDL BioPharma, Inc. PDLI Stock Holding History

Caxton Associates (New York)’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-87,446	Closed	-$275K	–	378
2020 Q3	$275K	Buy	+87,446	New	+$279K	0.03%	211
2020 Q1	–	Sell	-262,508	Closed	-$852K	–	663
2019 Q4	$852K	Buy	262,508 +186,488	+245%	+$541K	0.12%	105
2019 Q3	$164K	Sell	76,020 -7,040	-8%	-$18.8K	0.03%	355
2019 Q2	$261K	Sell	83,060 -123,413	-60%	-$400K	0.03%	314
2019 Q1	$768K	Buy	+206,473	New	+$697K	0.11%	95
2018 Q3	–	Sell	-45,069	Closed	-$105K	–	575
2018 Q2	$105K	Buy	+45,069	New	+$126K	0.01%	360

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

Caxton Associates (New York)'s PDLI Position: Q4 2020 in Review

Caxton Associates (New York) sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 87,446 shares — an estimated $275K sold.

Caxton Associates (New York) first reported a position in PDLI in Q2 2018 and held it in 6 quarters. The position peaked at $852K in Q4 2019. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Caxton Associates (New York) reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Caxton Associates (New York) sold 87,446 PDL BioPharma, Inc. shares in Q4 2020, an estimated $275K.
Caxton Associates (New York) first reported a position in PDL BioPharma, Inc. in Q2 2018 and held it in 6 quarters.
Caxton Associates (New York)'s PDL BioPharma, Inc. position peaked at $852K in Q4 2019.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Caxton Associates (New York)'s 13F filing for Q4 2020, filed 16 Feb 2021.